International Journal of Pediatrics / 2009 / Article / Tab 3

Clinical Study

Characterization of Acute Lymphoblastic Leukemia Subtypes in Moroccan Children

Table 3

Immunophenotypic profiles of 275 de novo acute lymphoblastic leukaemia.*

Markers T-cell ALL pB-cell ALL

CD1a+45/56 (80.4)
sCD3+49/59 (83.1)0/216 (0.0)
cCD3+57/57 (100)0/216 (0.0)
CD4+42/51 (82.4)
CD5+54/55 (98.2)
CD7+59/59 (100)7/216 (3.2)
CD8+32/52 (61.5)
CD10+10/47 (21.3)197/216 (91.2)
cyCD79a+0/48 (0.0)162/162 (100)
CD19+1/59 (1.7)216/216 (100)
CD20+0/8 (0.0)26/48 (54.2)
CD22+1/47 (2.1)216/216 (100)
CyIg+18/58 (31.0)
SIg+2/58 (3.5)
TdT+31/44 (70.5)142/158 (89.8)
CD34+25/59 (42.4)160/216 (74.1)
HLA-DR+4/39 (10.3)152/155 (98.1)
CD13+13/59 (22)100/216 (46.3)
CD33+9/49 (15.3)75/216 (34.7)
CD13+,CD33+2/59 (3.4)51/216 (23.6)
CD13-,CD33+7/59 (11.9)24/216 (11.1)
CD13+,CD33-11/59 (18.6)49/216 (22.7)
CD13+ and/or CD33+20/59 (33.9)124/216 (57.4)
CD13-, CD33-39/59 (66.1)92/216 (42.6)
CD45+59/59 (100)187/216 (87)

ALL: acute lymphoblastique leukaemia, : not applicable, MPO: myeloperoxidase, TdT: terminal deoxynucleotidyl transferase, cy: cytoplasmique, s: surface, +: positive, : negative, Ig: immunoglobulin. Result are given as number positive/number tested (% positive). Mature B-cell ALL excluded.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.